Skytrofa

Chemical Namelonapegsomatropin-tcgd
Dosage FormInjection (subcutaneous; 3 mg, 3.6 mg, 4.3 mg, 5.2 mg, 6.3 mg, 7.6 mg, 9.1 mg, 11 mg, 13.3 mg)
Drug ClassHormones
SystemEndocrine
CompanyAscendis Pharma Inc.
Approval Year2021

Indication

  • For the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Skytrofa (lonapegsomatropin-tcgd) Prescribing Information2021Ascendis Pharma Inc., Palo Alto, CA
Document TitleYearSource
Weekly lonapegsomatropin in treatment-naïve children with growth hormone deficiency: The phase 3 heiGHt trial.2021The Journal of Clinical Endocrinology & Metabolism